Clinical trial
International Safety and Efficacy Study of Aztreonam for Inhalation Solution…
NCT00112359 · Gilead Sciences, Industry · Completed
Key facts
| NCT number | NCT00112359 |
|---|---|
| Title | International Safety and Efficacy Study of Aztreonam for Inhalation Solution (AZLI) in Cystic Fibrosis Patients With P. Aeruginosa |
| Official title | A Phase 3, Double-Blind, Multicenter, Multinational, Randomized, Placebo-Controlled Trial Evaluating Aztreonam Lysinate for Inhalation in Cystic Fibrosis Patients With Pulmonary Pseudomonas Aeruginosa (AIR-CF1) |
| Acronym | AIR-CF1 |
| Lead sponsor | Gilead Sciences, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Cystic Fibrosis |
| Intervention type | Drug |
| Interventions | AZLI 75 mg three times a day (TID), Placebo three times a day (TID) |
| Enrollment | 166 |
| Start date | May 1, 2005 |
| Primary completion | Apr 1, 2007 |
| Completion | Apr 1, 2007 |
| First posted | Jun 2, 2005 |
| Last update posted | Apr 21, 2011 |
| Countries | Australia, Canada, New Zealand, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: